4.65 DESTINY BREAST 04 - A complex trial to deconstruct
Release Date:
My take on the standing ovation for DESTINY Breast 04
Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low
4.65 DESTINY BREAST 04 - A complex trial to deconstruct